Welcome to our dedicated page for Liquidia SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liquidia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liquidia's regulatory disclosures and financial reporting.
Liquidia Corp General Counsel Russell Schundler reported both equity awards vesting and a small share sale. He exercised performance stock units into a total of 10,167 shares of common stock at an exercise price of $0.00 per share.
On April 13, 2026, he sold 13,692 shares of common stock in an open-market transaction at $38.37 per share under a pre-arranged Rule 10b5-1 trading plan. According to the footnotes, these shares were sold to cover taxes tied to earlier RSU and PSU settlements. After these transactions, he directly holds 610,532 shares of Liquidia common stock and indirectly holds 14,500 shares through his spouse.
Liquidia Corp Chief Executive Officer Roger Jeffs reported a mix of equity vesting and share sales. He exercised performance stock units that converted into 28,167 shares of common stock at a conversion price of $0.00 per share, reflecting compensation-based awards rather than market purchases.
On the same date, 21,433 common shares were sold at a volume-weighted average price of $40.1193 per share through Serendipity BioPharma LLC, which Jeffs manages, with sole voting and dispositive power. A footnote states these shares were sold to cover taxes on vested RSUs and PSUs pursuant to a Rule 10b5-1 plan. Separately, he later sold 32,744 directly held shares at $38.37 per share under another Rule 10b5-1 trading plan and continued to hold 1,137,599 common shares directly afterward.
Insider sale notice: A Form 144 for LQDA reports an intended sale of 3,000 shares via exercise of stock options on 04/14/2026 for cash. The filing also lists recent Rule 10b5-1 sales by Michael Kaseta: 23,821 shares on 04/10/2026 for $956,248.79, 133,789 shares on 04/09/2026 for $5,383,388.40, and 1,165 shares on 03/02/2026 for $35,625.70.
Liquidia Corp Chief Executive Officer Roger Jeffs reported an open-market sale of 25,000 shares of Common Stock at an average price of $40.1155 per share. The transaction was executed indirectly through an affiliated entity and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025.
After the sale, Jeffs has 1,142,176 shares held directly and additional indirect holdings of 1,516,667 and 46,595 shares through entities associated with him. Footnotes also note substantial unvested RSU awards from grants made between January 2023 and January 2026, and that 10,696 shares previously acquired under the company’s Employee Stock Purchase Plan were rescinded due to ineligibility.
Liquidia Corp CFO and COO Michael Kaseta reported an exercise-and-sell transaction in company stock. He exercised stock options covering a total of 133,789 shares of common stock at exercise prices ranging from $2.54 to $2.97 per share and then sold 133,789 shares at a volume-weighted average price of $40.2379 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2025. After these transactions, he directly holds 411,855 shares of common stock, which include various blocks of unvested restricted stock units and shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
Serendipity Biopharma LLC filed a Rule 144 notice reporting resale activity in common stock. The filing lists 10b5-1 sales: 25,000 shares sold on 04/09/2026 for $1,002,887.50 and an earlier sale of 66,610 shares on 01/12/2026 for $2,493,212.30. The broker listed is Morgan Stanley Smith Barney LLC and the filing references NASDAQ.
Michael Kaseta reported insider transactions including sales under a Rule 10b5-1 plan and an option exercise. The filing lists 10b5-1 sales on 04/09/2026, 03/02/2026, and 01/12/2026 with share counts and gross proceeds shown below. It also records an exercise of stock options for 23,821 shares on 04/10/2026 with cash consideration.
Serendipity Biopharma LLC files a Form 144 reporting proposed sales of Common Stock. The filing lists a proposed sale of 25,000 shares through Morgan Stanley Smith Barney LLC and discloses 66,610 shares sold during the prior three months. Transaction dates include 11/18/2020 and 01/12/2026.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice relating to 133,789 shares of Common stock tied to an exercise of stock options on 04/09/2026, with cash payment indicated. The excerpt also lists previous reported sales by Michael Kaseta: 1,165 shares on 03/02/2026 and 36,932 shares on 01/12/2026.
Canaan VIII, L.P., an investment fund associated with Liquidia director Stephen M. Bloch, sold 70,234 shares of Liquidia common stock in open-market transactions. The sales occurred on March 26–27 at weighted average prices ranging from about $35 to $37 per share across several trades.
After these sales, entities tied to the fund reported holding 2,188,935 shares indirectly, while Bloch also reported 65,712 shares held directly. Bloch disclaims beneficial ownership of the fund-held shares except for his pecuniary interest and did not participate in the investment decision due to a communications-screen policy.